Completed from United States
The Advanced Pharmacovigilance Professional Certificate exceeded my expectations. The curriculum was precisely aligned with my goal of mastering signal detection and risk management, and the modules on MedDRA coding and ICH E2E guidelines gave me hands‑on expertise I could apply immediately at my pharmaceutical company. The case‑study workbook, especially the real‑world adverse‑event reports from the U.S. FDA database, helped me practice root‑cause analysis in a realistic setting. All materials were up‑to‑date and presented with clear, professional visuals, which made complex regulatory concepts easy to digest. Overall, the learning experience was seamless, and I feel fully equipped to lead our drug‑safety team.
Fiquei muito satisfeito com o curso da Stanmore School of Business. Eu queria entender melhor como fazer a avaliação de risco de medicamentos e o programa entregou exatamente isso. As aulas práticas sobre o uso do EudraVigilance e a criação de relatórios de segurança me deram confiança para aplicar no meu trabalho na indústria farmacêutica brasileira. Os materiais são bem organizados, com vídeos curtos e exemplos de casos reais que facilitam o aprendizado. Foi uma experiência bem leve, mas muito útil, e agora consigo explicar os processos de farmacovigilância para a minha equipe com mais clareza.
Wow – this course was exactly what I needed to boost my career in drug safety! The lessons on signal detection using statistical tools were presented with such enthusiasm that I actually looked forward to the quizzes. I especially loved the interactive simulation where we had to submit a Periodic Safety Update Report (PSUR) to the European Medicines Agency; it felt like real‑world work. The reading pack included the latest EU guidelines and they were explained in plain language, which made a huge difference. Overall, the experience was energising and I left the program feeling ready to take on a senior pharmacovigilance role.
The Advanced Pharmacovigilance Professional Certificate offered a thorough and detailed exploration of drug safety processes. My primary aim was to gain practical skills in adverse event case processing, and the course delivered step‑by‑step tutorials on using the WHO VigiBase platform, which I have already implemented at my organization in Mumbai. The study materials included up‑to‑date ICH guidelines, annotated flowcharts, and downloadable templates for risk‑management plans, all of which were highly relevant to the Indian regulatory context. The instructor’s detailed explanations and the extensive reference library made the learning experience comprehensive and satisfying.
